Navigation Links
Unique Extracellular Matrix Used in Patient Successfully Treated for Flesh Eating Bacteria

COLUMBIA, Md., April 17, 2013 /PRNewswire/ -- A patient diagnosed with necrotizing fasciitis was successfully treated and discharged after ACell MatriStem was used in an effort to save her leg from amputation, reported Marcie Fraser of Your News Now.

Jonna Rue went to the hospital when her foot became blood-red and swollen. A flesh eating bacteria was quickly destroying the tissues in her leg. Doctors intervened surgically to remove a great deal of tissue in an attempt to stop the bacteria from spreading. Amputation of her lower leg was considered due to the extent of damage to her leg.

"Given the amount of overall tissue loss, it was not looking promising to keep her leg," Dr. Peter Fisk , Community Care General Surgeon said.

The wound was treated and MatriStem, the only commercially available form of urinary bladder matrix (UBM), was applied. Six weeks after the extracellular matrix (ECM) was applied to the patient's leg, the tissue was healed enough to skin graft and close the wound. The physician determined that amputation was no longer necessary.

"It is quite a grounding moment when we learn that our products have been used to help patients like Ms. Rue and are happy that she is recovering nicely. It is with a sense of pride and excitement to see the clinical outcomes when our technology is used to treat patients," Rodney Bosley , ACell President & COO said. "Results like these are driving our growth following the record product sales ACell achieved in 2012."

Necrotizing fasciitis, a rare condition of the skin and subcutaneous tissues, can rapidly spread across the body, leading to amputation or death.

MatriStem Products are porcine-derived extracellular matrix that maintain and support a healing environment through constructive remodeling, are available by prescription only in particle and sheet forms. Refer to IFU supplied with each device for indications, contraindications, and precautions.

About ACell  ACell, Inc. offers the next generation of regenerative medicine through the development and commercialization of unique extracellular matrix products to repair and remodel damaged tissues in a broad range of applications. ACell's patented ECM devices address important clinical needs, while providing safe, effective, economical and therapeutic outcomes to the wound care and surgical communities. These devices, trademarked as MatriStem, are appropriate for acute wounds, chronic wounds and various surgical procedures. All MatriStem devices are made in the USA. For more information, call (800) 826-2926 or visit

SOURCE ACell, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Launched, a Unique Life Science Business Networking Site
2. ZyGEM to Provide its Unique DNA and RNA Extraction Technology to Middle East Biomedical Innovator Saudi Diagnostics Ltd.
3. Unique salt allows energy production to move inland
4. All Global Partners With HealthEngage to Provide Unique Web 2.0 Patient Insights
5. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
6. Unique properties of graphene lead to a new paradigm for low-power telecommunications
7. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
8. PathoGenetix Names Ann Merrifield as Chief Executive Officer and Prepares to Launch Unique Bacterial Identification Technology
9. Boston College researchers unique nanostructure produces novel plasmonic halos
10. Unique Bed Bug Extermination Solution Revealed To The Public and Its Complimentary Sample Offered, Shares Details Where to Get It
11. Verdad Media’s Unique MANIS Technology Means Better Reputation Management Results for Clients
Post Your Comments:
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 Cepheid ... will be speaking at the following conference, and invited ... New York, NY      Tuesday, December 1, 2015 ... New York, NY      Tuesday, December 1, 2015 ... Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
(Date:11/24/2015)... 2015 SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
Breaking Biology News(10 mins):